Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a Authors: Sebastian Moreira, Laura Clow, Emily Coles-Piper, Alison Donald, Christer Janson, Dave Singh, David Slade, Pankaj Tiwari, Stephen Weng, Maximilian Plank Published: 2026 ABSTRACT AbstractIntroductionClimate change is a global threat. Propellant hydrofluoroalkane (HFA)-134a in metered-dose inhalers (MDIs) contributes to healthcare-related greenhouse gas emissions. HFA-152a is a new propellant with ~90% lower global warming potential than HFA-134a. Two phase I studies (NCT06433908/NCT06433921) compared the pharmacokinetics (PK), pharmacodynamics (PD) and safety of salbutamol MDI with HFA-152a or HFA-134a.MethodsRelative bioavailability (Study 1): healthy adults received single salbutamol doses (200/800 µg) via MDI with HFA-152a or HFA-134a. Primary PK endpoints were areas under the plasma concentration–time curve (0–30 min (AUC)0–30 min, zero to infinity (AUC0–∞) and maximum plasma concentration (Cmax)). Relative PD potency via methacholine challenge (Study 2): patients with mild asthma received MDI placebo and salbutamol doses (100/200/400 µg) with HFA-152a or HFA-134a. The primary PD endpoint was provocative methacholine concentration (PC) causing ≥20% (PC20) forced expiratory volume in 1 s reduction.ResultsStudy 1: 60 participants (30 per cohort) enrolled. In cohort 1 (200 µg), AUC0–30 min was within the predefined PK bioequivalence (BE) range (0.80–1.25); in cohort 2 (800 µg), AUC0–∞ and Cmax were within the BE range. Study 2: 21 participants enrolled. PD relative potency of HFA-152a was within the predefined BE range (0.67–1.50). No serious treatment-related adverse events (AEs) were reported; all AEs were mild and occurred at similar frequencies with both propellants.ConclusionsSalbutamol with HFA-152a demonstrated equivalence in key PK and PD parameters, as well as a similar safety profile to salbutamol with HFA-134a, supporting salbutamol MDI with HFA-152a as a therapeutically equivalent, low-carbon replacement. WHAT IS ALREADY KNOWN ON THIS TOPIC People living with chronic respiratory diseases are disproportionately affected by climate change. People living with chronic respiratory diseases are disproportionately affected by climate change. Propellants HFA (hydrofluoroalkane)-134a and HFA-227ea used in conventional metered dose inhalers (MDIs) are potent greenhouse gases that have a 100-year global warming potential (GWP) (GWP100) 1530-fold and 3600-fold greater than that of carbon dioxide, respectively. Propellants HFA (hydrofluoroalkane)-134a and HFA-227ea used in conventional metered dose inhalers (MDIs) are potent greenhouse gases that have a 100-year global warming potential (GWP) (GWP100) 1530-fold and 3600-fold greater than that of carbon dioxide, respectively. New treatment strategies aimed at making asthma care more environmentally sustainable are helpful; a salbutamol MDI that replaces HFA-134a with the low-GWP propellant HFA-152a (GWP100 of 164) is in development to reduce the carbon footprint of each inhaler by >90%. New treatment strategies aimed at making asthma care more environmentally sustainable are helpful; a salbutamol MDI that replaces HFA-134a with the low-GWP propellant HFA-152a (GWP100 of 164) is in development to reduce the carbon footprint of each inhaler by >90%. WHAT THIS STUDY ADDS In two phase I studies, salbutamol MDI with HFA-152a or HFA-134a showed similar pharmacokinetics, pharmacodynamics and safety outcomes, supporting the therapeutic equivalence of salbutamol MDI with HFA-152a. In two phase I studies, salbutamol MDI with HFA-152a or HFA-134a showed similar pharmacokinetics, pharmacodynamics and safety outcomes, supporting the therapeutic equivalence of salbutamol MDI with HFA-152a. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Both studies represent an important step towards ensuring patient access to a salbutamol MDI with a propellant that lowers carbon emissions by >90%, offering a valuable opportunity to reduce environmental impact. Both studies represent an important step towards ensuring patient access to a salbutamol MDI with a propellant that lowers carbon emissions by >90%, offering a valuable opportunity to reduce environmental impact. Introduction Climate change is recognised by the WHO as a fundamental threat to global health, with the potential to undo decades of health progress.1 People living with chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are disproportionately affected because they are especially vulnerable to weather extremes, deteriorating air quality, changes in pathogen distribution (eg, fungi), shifting allergen profiles and longer allergy seasons.2 3 Short-acting β2-agonists (SABAs) remain essential for the rapid relief of bronchospasm in asthma and COPD for most patients.4 5 In the 12 months prior to June 2019, SABAs represented 59% of all inhaled therapies for these conditions worldwide.6 The predominant method of delivery for SABAs is through pressurised metered-dose inhalers (MDIs), which use hydrofluorocarbon (HFC) propellants. According to the Intergovernmental Panel on Climate Change 2021, the propellants hydrofluoroalkane (HFA)-134a and HFA-227ea used in conventional MDIs are potent greenhouse gases (GHG) that have a 100-year global warming potential (GWP) (GWP100) 1530-fold and 3600-fold greater than that of carbon dioxide (CO2), respectively.7 MDIs using these propellants therefore have higher carbon footprints than propellant-free dry-powder inhalers or soft-mist inhalers.8 9 The GWP of currently used HFCs has led to their phase-down under the Kigali Amendment to the Montreal Protocol.10 Legislation for this phase-down has been implemented across Europe with the European Union fluorinated-gas legislation (which covers HFCs), and other countries are considering adopting similar measures.1113 New treatment strategies aimed at making respiratory care more environmentally sustainable are helpful, including inhalers with lower GHG emissions and reducing the use of SABA inhalers with a high carbon footprint. However, the real-world accessibility of such strategies must be considered, particularly given that SABA MDIs remain the only asthma treatment accessible to patients in many parts of the world.14 Furthermore, current treatment strategies for asthma recommend that inhaler selection balances environmental impact with patients’ ability to use and preferences for a particular device.5 A salbutamol MDI that replaces HFA-134a with the low-GWP propellant, HFA-152a (GWP100 of 164), is in development.7 This planned salbutamol MDI has the potential to reduce the GWP of each inhaler by more than 90% (25 kgCO2e) relative to using HFA-134a, according to a recent lifecycle analysis.15 16 Another recent study confirmed the bioequivalence (BE) of HFA-152a and HFA-134a for beclometasone dipropionate actuation in healthy volunteers.17 Optimising asthma control and choosing a low-carbon inhaler device should go hand in hand. Therefore, the development of salbutamol MDI with HFA-152a represents a crucial step towards continued patient access to effective reliever therapy while reducing the carbon footprint of treatment. Here, we present the results of two studies: the first study had a primary objective of comparing the pharmacokinetic (PK) relative bioavailability of salbutamol delivered via MDI with HFA-152a versus the currently available HFA-134a. The primary objective of the second study was to compare the relative potency of each salbutamol formulation at protecting from bronchoconstriction elicited by methacholine challenge. Methods Relative bioavailability study Study design This was a randomised, open-label, single-dose, two-cohort, four-way crossover study, conducted at the Clinical Research Unit in Groningen, the Netherlands, between 4 June and 22 October 2024 (figure 1A). Study design of (A) the relative bioavailability study and (B) the pharmacodynamic relative potency via methacholine challenge study. aParticipants received each salbutamol MDI formulation twice; bseven randomised treatment sequences were assessed with each participant receiving all seven treatments, separated by 2–7-day washout periods. HFA, hydrofluoroalkane; MDI, metered-dose inhaler; R, reference; RTTR, reference, test, test, reference; T, test; TP, treatment period; TRRT, test, reference, reference, test. Participants were enrolled in one of two cohorts to receive salbutamol administered without a spacer device. Participants in cohort 1 received salbutamol 200 µg MDI with HFA-152a or HFA-134a, administered as 2×100 µg (ex-valve dose) actuations at 20 s intervals. Participants in cohort 2 received salbutamol 800 µg MDI with HFA-152a or HFA-134a, administered as 8×100 µg actuations at 20 s intervals. The salbutamol 200 µg dose was chosen as representative of the typical prescribed and labelled dose (based on one or two inhalations); the 800 µg dose was included to be close to the maximum recommended total daily dose and facilitate comparison to historical data. Participants in both cohorts were randomly assigned to one of two treatment sequences: TRRT (test, reference, reference, test) or RTTR (reference, test, test, reference), where T is test (HFA-152a) and R is reference (HFA-134a). Thus, each participant received each salbutamol MDI formulation twice. The intervention period was 10 days with dosing on days 1, 4, 7 and 10, each separated by a 72-hour washout period. Patient and public involvement Given the quantitative and well-defined nature of the study, patients and members of the public were not involved in the design, conduct, reporting or dissemination plans of this research. Participants Healthy male or female volunteers aged 18–55 years were eligible for inclusion. Additional eligibility criteria included a body mass index (BMI) of 18.5–29.9 kg/m², body weight between 45 and 110 kg and a forced expiratory volume in 1 s (FEV₁) of ≥80% of predicted. Full eligibility criteria are listed in the online supplemental materials. Endpoints The primary PK endpoints were area under the plasma concentration-time curve (AUC) from time 0 to 30 min (AUC0–30-min), AUC from zero to infinity (AUC0–∞) and maximum plasma concentration (Cmax) of salbutamol for each MDI formulation. Secondary endpoints included time to salbutamol Cmax (Tmax) and the elimination half-life (t1/2) of salbutamol. On each of the four dosing days, blood samples were taken predose and postdose at 3, 5, 10, 15, 20, 30 and 45 min, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours postdose for plasma salbutamol concentration determination. The lower limit of detection was 25 pg/mL validated through liquid chromatography–mass spectrometry (LC-MS) method. Safety endpoints included incidence of adverse events (AEs) and serious AEs (SAEs), change from baseline in 12-lead ECG recordings, and absolute values of clinical laboratory parameters and vital signs (blood pressure and pulse rate) at each assessed visit. Pharmacodynamic (PD) measures of interest were exploratory endpoints and included minimum serum potassium concentration, maximum heart rate (HR), and maximum HR-corrected QT interval (corrected using Fridericia’s formula (QTcF)). Statistical analyses A total of 30 participants were planned for enrolment in each cohort, with further information on sample size calculations included in the online supplemental materials. The PK parameters AUC0–30 min, AUC0–∞ and Cmax were analysed using a linear mixed effect model with sequence, treatment and period as fixed effect, and participant as a random effect. The resulting point estimates and their 90% CIs were back-transformed from the log scale to provide geometric mean ratios (GMRs) and corresponding 90% CIs for the ratio of salbutamol MDI with HFA-152a versus HFA-134a. The accepted BE range was 0.80–1.25 hour∙pg/mL18 for the 90% CI of GMRs for AUC0–30 min, AUC0–∞ and Cmax. PD parameters were analysed using a linear mixed effect model with treatment and period as fixed effect. Participants who withdrew early were not replaced and missing data were not imputed; blank fields in participant listings reflected unavailable data, except where entire visits were missing and excluded from analysis. ‘Not applicable’ and ‘Not evaluable’ responses were reported as such. PD relative potency via methacholine challenge study Study design This was a randomised, blinded, two-part, single-dose, seven-way crossover study, conducted at the Medicines Evaluation Unit in Manchester, UK, between 14 August 2024 and 24 October 2024 (figure 1B). Participants were randomised to one of seven treatment sequences of methacholine challenge and a single dose of salbutamol (100, 200 or 400 µg) or placebo MDI with HFA-152a (test) or HFA-134a (reference), each separated by 2–7-day washout periods. The salbutamol 100 and 200 µg doses were chosen as representative of the typical prescribed and labelled doses (based on one or two inhalations). However, previous studies have shown that dose separation between salbutamol 100 and 200 µg on methacholine challenge is relatively modest.19 Therefore, a 400 µg dose was included to ensure adequate sensitivity to detect potential differences in bronchodilator response arising from changes in the propellant formulation.20 Patient and public involvement Given the quantitative and well-defined nature of the study, patients and members of the public were not involved in the design, conduct, reporting or dissemination plans of this research. Participants Male or female participants with a diagnosis of mild asthma for ≥6 months, aged 18–65 years were eligible for inclusion. Additional eligibility criteria included hyper-responsivity to provocative concentration (PC) of methacholine causing ≥20% (PC20) fall in FEV1 (ie, PC20<8 mg/mL), a BMI of 19.0–35.0 kg/m², body weight between ≥50 kg and a FEV₁ of ≥80% of predicted. The FEV₁ criterion was assessed at the start of each treatment period prior to methacholine challenge and prebronchodilator FEV1 was required to be ±10% of the baseline FEV1 value at screening, for participants to continue in the study. SABA and long-acting β2-agonist-containing medications had to be withheld for ≥8 and ≥48 hours, respectively, at screening and during treatment periods. Participants were excluded if they experienced a severe exacerbation in the 6 months prior to screening and ≤1 severe exacerbation in the 12 months prior to screening. Full eligibility criteria are listed in the online supplemental materials. Endpoints The primary endpoint was the relative potency and variability of dose-response on bronchoprotection as measured by the PC20. Secondary systemic PD endpoints included QTcF interval, peak HR, and minimum serum potassium concentration. Safety endpoints included incidence of AEs and SAEs, change from baseline in 12 lead ECG recordings, and absolute values of clinical laboratory parameters and vital signs (blood pressure and pulse rate) at each assessed visit. Statistical analyses A total of 21 participants were planned for enrolment, with further information on sample size calculations included in the online supplemental materials. The primary endpoint, methacholine PC20, was analysed using a log-linear model with drug dose as fixed effect and participant as random effect. The relative potency was assessed through the appropriate combination of the estimates of the model parameters, and its 90% CI was estimated using the delta method based on Taylor series approximations. Assumption of parallelism between test and reference dose-response was assessed using F-test. The accepted BE range was observed between 0.67 and 1.50.20 The primary analysis used a hypothetical strategy (period values set to missing) for handling intercurrent events of study treatment discontinuation due to any reason, occurrence of emesis or coughing on dosing, dosing error (including salbutamol and methacholine timing): fewer than or more than prescribed dose, use of prohibited rescue medication. Systemic PD parameters were analysed descriptively. Results Relative bioavailability study Study population Of the eligible healthy volunteer participants, 30 were enrolled into each cohort. Most participants completed the study in both cohort 1 (n=28/30; 93.3%) and cohort 2 (n=29/30; 96.7%) (online supplemental figure 1). Participant characteristics are presented in online supplemental table 1. In cohort 1, 60% of participants were female and had a mean (SD) age of 26.2 (5.7) years; in cohort 2, 50% were female with a mean (SD) age of 31.0 (8.6) years. The mean (SD) BMI for cohort 1 and 2 were 23.2 (2.0) and 24.5 (3.2) kg/m2. PK parameters of salbutamol MDI with HFA-152a or HFA-134a After administration of salbutamol MDI with HFA-152a or HFA-134a, most participants in cohort 1 and all participants in cohort 2 showed measurable salbutamol plasma concentrations at 3 min postdose, indicating rapid lung absorption (figure 2). The mean plasma concentrations of salbutamol rapidly increased after dosing, with similar increases observed up to 30 min postdose. Mean (SD) salbutamol plasma concentration over time plotted as a semilog scale for (A) cohort 1 (salbutamol 200 µg) and (B) cohort 2 (salbutamol 800 µg) in the relative bioavailability study. HFA, hydrofluoroalkane; LLQ, lower limit of quantification; MDI, metered-dose inhaler. The relative bioavailability between salbutamol MDI with HFA-152a and HFA-134a at the lower dose (salbutamol 200 µg; cohort 1) met BE criteria for AUC0–30 min (GMR: 0.96 (90% CI 0.87 to 1.07)), indicating equivalent lung absorption, while the ratios for AUC0–∞ (1.29 (1.18 to 1.42)) and upper CI for Cmax (1.23 (1.12 to 1.36)) were slightly outside the bounds of BE. At the higher dose (salbutamol 800 µg; cohort 2), ratios for AUC0–∞ (1.20 (1.16 to 1.25)) and Cmax (1.13 (1.02 to 1.24)) were within the accepted range, while the lower CI for AUC0–30 min fell slightly below the lower limit of BE (0.95 (0.77 to 1.16)) (figure 3). PK of single dose of salbutamol (200 or 800 µg) MDI with HFA-152a or HFA-134a in the relative bioavailability study (red rectangles represent parameters with the range of bioequivalence). aSalbutamol 200 µg with HFA-152a MDI (AUC0–30 min), n=29; bsalbutamol 800 µg with HFA-134a MDI, n=29; cwithin bioequivalence range (CI limits: 0.80–1.25). %CVwr, within-subject coefficient of residual variation; AUC, area under the curve; Cmax, maximum plasma concentration; HFA, hydrofluoroalkane; LS, least squares; MDI, metered-dose inhaler; PK, pharmacokinetic. In cohort 1 (salbutamol 200 µg), median Tmax ranged from 1.25 to 2.00 hours for HFA-152a and from 1.00 to 2.00 hours for HFA-134a across study days. In cohort 2 (salbutamol 800 µg), median Tmax was 1.50 hours for HFA-152a and 1.25–1.50 hours for HFA-134a. After reaching peak concentrations, plasma salbutamol levels declined with similar terminal elimination half-lives across treatments: in cohort 1, t½ was 7.22–8.17 hours for HFA-152a and HFA-134a; in cohort 2, t½ was 7.57–8.56 hours for HFA-152a and HFA-134a. Safety of salbutamol MDI with HFA-152a or HFA-134a AEs were reported in 23 participants (76.7%) in cohort 1 and in 27 participants (90.0%) in cohort 2 (online supplemental table 2). In cohort 1, one SAE (3.3%) of conversion disorder unrelated to study treatment was reported, with no SAEs reported in cohort 2. No participant discontinued due to an SAE or died during the study. Treatment-related AEs occurred in two participants (6.7%) in cohort 1 (TRRT sequence: throat irritation; RTTR sequence: allergic respiratory disease) and nine participants (30.0%) in cohort 2 (TRRT sequence: headache, paraesthesia oral, cough, dry throat, dyspnoea, nausea; RTTR sequence: headache, paraesthesia oral, dizziness, dry throat, dyspnoea, HR increased). In cohort 1, there were no clinically significant findings with regard to ECG, clinical laboratory measurements or vital signs. There were no clinically significant findings in clinical laboratory measurements or vital signs in cohort 2; one participant in cohort 2 had a clinically significant ECG finding on day 7. PD parameters of salbutamol MDI with HFA-152a or HFA-134a PD profiles were nearly identical between HFA-152a and HFA-134a formulations in both cohorts, with no notable differences in geometric least squares means or GMRs for minimum serum potassium concentration, maximum HR or QTcF interval parameters (online supplemental table 3). PD relative potency via methacholine challenge study Study population Of the screened participants with mild asthma, 21 were enrolled (online supplemental figure 2). Most participants completed the methacholine challenge, with 100% of participants completing each treatment period for HFA-152a and 90% (n=19/21) completing each treatment period for HFA-134a. Participant characteristics are presented in online supplemental table 4. In total, 76% of participants were male and had a mean (SD) age of 41.1 (13.08) years, with a mean (SD) BMI of 26.0 (4.4) kg/m2. Relative potency of salbutamol MDI with HFA-152a or HFA-134a Salbutamol MDI with HFA-152a had PD equivalence to the current MDI with HFA-134a based on modelling of bronchoprotection after provocation with methacholine challenge (estimate: 1.0244; SE: 0.1914 (90% CI 0.6943 to 1.3545)), which was within the accepted BE range (figure 4). A similar dose-response relationship was observed between salbutamol MDI with HFA-152a and HFA-134a with regard to methacholine PC20, supporting PD equivalence between the two formulations of salbutamol (figure 4). Relative potency of salbutamol MDI with HFA-152a versus HFA-134a PD relative potency via the methacholine challenge study. aLog 2 transformed PC20 (mg/mL); bsalbutamol MDI with HFA-152a (n=21), salbutamol MDI with HFA-134a (n=19). The statistical analysis is performed using a log-linear model with drug dose as fixed effect and subject as random effect. FEV1, forced expiratory volume in 1 s; HFA, hydrofluoroalkane; MDI, metered-dose inhaler; PC20, provocative concentration of methacholine that results in ≥20% fall in FEV1. Systemic PD parameters of salbutamol MDI with HFA-152a or HFA-134a Geometric means for minimum serum potassium concentration, maximum HR and maximum QTcF intervals were similar between placebo, salbutamol MDI with HFA-152a and the formulation with HFA-134a, with overlapping CIs (table 1). Table 1Systemic PD outcomes for salbutamol MDI with HFA-152a or HFA-134a in the PD relative potency via the methacholine challenge studyPlacebo(N=21)Salbutamol MDI with HFA-152a (N=21)Salbutamol MDI with HFA-134a (N=21)100 µg200 µg400 µg100 µg200 µg400 µgMinimum serum potassium (mmol/L), geometric mean (95% CI)3.94(3.84 to 4.05)3.91(3.79 to 4.04)3.91(3.82 to 4.01)3.95(3.84 to 4.06)3.99(3.89 to 4.09)3.97(3.88 to 4.07)3.93(3.84 to 4.03)Maximum HR (beats/min),geometric mean (95% CI)66.29(62.02 to 70.86)68.49(63.75 to 73.57)67.93(62.92 to 73.32)67.89(63.15 to 73.00)67.89(63.16 to 72.97)67.52(62.96 to 72.42)65.25(61.36 to 69.39)Maximum QTcF interval (ms), geometric mean (95% CI)430.93(423.39 to 438.62)428.95(420.68 to 437.38)427.58(419.28 to 436.03)429.12(422.20 to 436.16)428.60(420.87 to 436.46)433.06(425.00 to 441.28)431.48(422.84 to 440.30)HFA, hydrofluoroalkane; HR, heart rate; MDI, metered-dose inhaler; PD, pharmacodynamic; QTcF, heart rate-corrected QT interval using Fridericia’s formula. Systemic PD outcomes for salbutamol MDI with HFA-152a or HFA-134a in the PD relative potency via the methacholine challenge study HFA, hydrofluoroalkane; HR, heart rate; MDI, metered-dose inhaler; PD, pharmacodynamic; QTcF, heart rate-corrected QT interval using Fridericia’s formula. Safety of salbutamol MDI with HFA-152a or HFA-134a AEs were reported in 11 participants (52%) overall, with no SAEs reported (online supplemental table 5). No AEs were adjudicated as related to salbutamol MDI with HFA-152a or HFA-134a during any active treatment period. One participant (5%) reported a drug-related AE, productive cough, after receiving placebo. No AEs led to treatment discontinuation. Overall, there were no clinically meaningful changes in laboratory tests, vital signs or ECGs. Discussion These two separate phase I studies evaluated BE of salbutamol MDI with low-GWP propellant HFA-152a, compared with the currently available propellant HFA-134a, using PK and PD endpoints, along with assessments of safety. PK was equivalent in key endpoints associated with efficacy, and PD measures of bronchoprotection were equivalent between the two propellants, with safety outcomes being consistent across both studies. Together, findings from these studies support the therapeutic equivalence of salbutamol MDI with the low-GWP propellant HFA-152a. In the relative bioavailability study, plasma salbutamol concentrations increased rapidly (within 3 min) following inhalation in cohorts 1 (salbutamol 200 µg) and 2 (salbutamol 800 µg), with peak levels occurring after 1.25–2.00 hours, consistent with rapid pulmonary absorption and in line with the PK of salbutamol.21 The PK profile of salbutamol delivered with propellant HFA-134a reported in our study was consistent with previous HFA-134a data.22 23 Overall, the results demonstrated that the PK of salbutamol after administration with salbutamol MDI with HFA-152a were comparable with salbutamol MDI with HFA-134a at both doses studied. Importantly, at the 200 µg dose, PK BE criteria were met in terms of the parameter most closely associated with efficacy, AUC0–30 min,20 providing evidence to support an evaluation of the two formulations in terms of therapeutical equivalence from an efficacy perspective and an assessment of whether the two formulations can be expected to perform similarly. Salbutamol 200 µg PK values for parameters aligned with efficacy (Cmax) and safety (AUC0–∞) were consistent with levels previously observed for HFA-134a,17 and although beyond standard regulatory BE limits, were not considered clinically relevant in the context of historical HFA-134a data.22 23 Additionally, analysis at the 800 µg dose level showed that all three of the PK parameters met the accepted BE criteria, further supporting similarity from an efficacy and safety perspective. The results of the PD study provide additional evidence that the small relative increase of Cmax and AUC0–∞ for salbutamol administered with propellant HFA-152a in the PK study, as evidenced by minor excursion above the 90% CI upper limit of the standard BE criteria for the 200 µg dose, is not clinically relevant. Importantly, based on the primary endpoint of PC20, the results of the study demonstrate BE of the two formulations with a GMR and 90% CI contained completely between the established BE criteria of 0.67–1.50. An overall similar dose response relationship between the two formulations across the studied dose range of 100, 200 and 400 µg (as evidenced by overlapping 95% CIs at each dose level) further supports comparable bronchoprotection between the two formulations. Sensitivity of the assay was demonstrated as we observed greater separation between the salbutamol 100 and 400 µg doses than between the propellants at the same dose. This study was not formally powered; however, given that the 90% CI fell within the prespecified limits set by recent global standards for orally inhaled products, evaluation of the primary endpoint is considered robust and scientifically sound. In both studies, PD markers associated with β2 receptor agonism, including HR, serum potassium and QTc interval, were nearly identical between the salbutamol MDIs with HFA-152a and HFA-134a across studied salbutamol doses, consistent with previously reported systemic effects.24 25 Treatment-related AEs were mild and occurred at similar frequencies in the relative bioavailability study, while no treatment-related AEs were reported in the PD equivalence via the methacholine challenge study. Confirmation of the safety and tolerability of salbutamol MDI with HFA-152a in the longer term has been completed, with a separate phase III study (NCT06261957). A strength of both studies was that the sample size was adequately powered to demonstrate BE in accordance with regulatory guidelines.18 20 Key strengths of the relative bioavailability study were the use of a replicate crossover design, which can minimise any carry-over effect, and the increased assay sensitivity, which was able to fully characterise the entire PK profile. A strength of the PD study was the use of a stringent threshold, which was used to quantitate airway hyperresponsiveness in patients with asthma who may experience bronchoconstriction.26 27 It is a highly sensitive test26 28 and is recommended by both the European Respiratory Society29 and the American Thoracic Society.30 Additionally, this study used a broad dose range (100, 200 and 400 µg), rather than a single dose, which enhanced the test sensitivity, allowing discrimination between test and reference products,31 and permitting characterisation of the dose-response curve, per recommendations.32 Limitations of the relative bioavailability study included healthy volunteers rather than participants from the target patient population. While this approach is standard for early PK/PD evaluations, it does limit the generalisability of the findings and should be considered when interpreting the results. Conclusions By demonstrating therapeutic equivalence, including both PK equivalence of lung absorption and PD equivalence of salbutamol MDI with the low-GWP propellant HFA-152a versus the currently available HFA-134a, these studies represent an important step towards supporting future patient access to salbutamol in an MDI while reducing the inhaler’s carbon emissions by over 90%. The transition to low-GWP inhalers offers a valuable opportunity to reduce environmental impact and optimise disease management. Supplementary material